You are here

Article Text

Article menu
Download PDFPDF
Ovarian Cancer
Utility Serum Marker HE4 for the Differential Diagnosis Between Endometriosis and Adnexal Malignancy
  1. Ignacio Zapardiel, PhD*,
  2. Mikel Gorostidi, MD†,
  3. Antonella Ravaggi, MD‡,
  4. Maria T. Allende, PhD§,
  5. Margarida Silveira, PhD∥,
  6. Daniel Abehsera, PhD* and
  7. Ronalds Macuks, PhD
  1. *Gynecologic Oncology Unit, La Paz University Hospital, Madrid;
  2. †Gynecology Department, Hospital Universitario Donostia Donostia, Pais Vasco, Spain;
  3. ‡Division of Gynecologic Oncology, Angelo Novicelli Institute for Molecular Medicine, University of Brescia, Brescia, Italy;
  4. §Tumoral Markers Unit, Asturias Central University Hospital, Oviedo, Spain;
  5. ∥Clinical Pathology Department, Portuguese Institute of Oncology of Lisbon, Lisbon, Portugal; and
  6. A. Kirhenstein’s Institute of Microbiology and Virology, Riga, Latvia.
  1. Address correspondence and reprint requests to Ignacio Zapardiel, PhD, Gynecologic Oncology Unit. La Paz University Hospital, Paseo Castellana 261, 28046, Madrid, Spain. E-mail: ignaciozapardiel@hotmail.com.

Abstract

Objective The aim of the study was to assess the utility of serum human epididymal secretory protein E4 (HE4) biomarker in the differential diagnosis of endometriosis and adnexal malignancies.

Methods Multicentric prospective observational study between January 2010 and December 2011 in 4 European centers (Italy, Portugal, Latvia, and Spain) was carried out. We collected 981 healthy patients diagnosed with adnexal patology and selected 65 patients diagnosed with endometriosis and analyzed their serum markers CA125, HE4, and Risk of Ovarian Malignancy Algorithm (ROMA) index. We also analyzed all cases of malignant histology and divided them according to CA125 levels (negative, ⩽35 U/mL; intermediate, >35–150 U/mL; and highly positive, >150 U/mL).

Results HE4 was positive only in 1.5% of cases, CA125 in 64.6%, and ROMA index in 14.1%. In the subgroup intermediate CA125 values, positive HE4 is very specific (91.2%) correctly classifying patients with benign disease, but with lower sensibility (66.1%); however, ROMA index showed a high sensibility (89.3%), with a false-positive rate of 42.8%.

Conclusions HE4 can be a very useful biomarker to exclude malignant disease in patients with endometriosis.

  • Ovarian cancer
  • Endometriosis
  • Screening
  • HE4
  • Human epididymis protein 4

https://doi.org/10.1097/IGC.0000000000000579

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • The authors declare no conflicts of interest.